Johnson & Johnson unveiled on Tuesday in a press release that it will be investing $2 billion in North Carolina to build a "state-of-the-art biologics manufacturing facility."
Vice President of Innovative Medicine Supply Chain Dapo Ajayi stated that having a "strong, global supply chain" is of utmost importance and added that with this investment the company further ensures its transformational medicines can be delivered to patients "reliably and efficiently."
The new facility "will expand production of Johnson & Johnson’s innovative biologic medicines in areas including oncology, immunology, and neuroscience," the company detailed. Construction is expected to start in the first six months of 2025.
